FX-322 for Sensorineural Hearing Loss

"Our company's assessment of FX-322 safety is 2 based off its Phase 2 status. This suggests that there are some existing data points to support the drug's security, though none confirming efficacy as yet."

"At present, this clinical trial is not recruiting patients, as evidenced by the information on clinicaltrials.gov. Originally posted in October 12th 2021 and last updated two days later, 165 other trials are actively searching for participants."

"This medical trial is recruiting 142 participants, from the age of majority up to 65 years old, with sudden hearing loss. Females must possess non-childbearing potential and use two forms of reliable contraception or abstain during the study period; males should wear a condom equipped with spermicide while participating in this research or remain celibate. Participants need to demonstrate adequate communication skills and commit to completing all necessary procedures as specified by investigators. Furthermore, patients have to have acquired adult onset sensorineural hearing loss based on noise-induced SNHL (NIHL) or idiopathic sudden SNHL (SSNHL). Furthermore, they must"

"Qualified individuals for this specific trial must be 18-65 years old. Conversely, 54 clinical trials are available to those under the age of majority and 129 studies offer support to seniors above 65 years old."

"Partaking in this trial is currently feasible at 25 medical sites, with Spartanburg, Amherst and Sarasota being some of the most notable. To reduce travel expenses while taking part in the study you should consider selecting a location closest to your home."